Stryker Co. (NYSE:SYK) Shares Bought by Kayne Anderson Rudnick Investment Management LLC

Kayne Anderson Rudnick Investment Management LLC lifted its position in Stryker Co. (NYSE:SYK - Free Report) by 2.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 70,488 shares of the medical technology company's stock after purchasing an additional 1,749 shares during the quarter. Kayne Anderson Rudnick Investment Management LLC's holdings in Stryker were worth $25,379,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Chicago Capital LLC grew its position in Stryker by 3.1% in the fourth quarter. Chicago Capital LLC now owns 195,052 shares of the medical technology company's stock worth $70,228,000 after acquiring an additional 5,841 shares during the period. Zhang Financial LLC boosted its holdings in Stryker by 55.0% during the 4th quarter. Zhang Financial LLC now owns 114,889 shares of the medical technology company's stock valued at $41,366,000 after acquiring an additional 40,784 shares during the period. Appleton Partners Inc. MA grew its position in Stryker by 5.0% in the 4th quarter. Appleton Partners Inc. MA now owns 29,222 shares of the medical technology company's stock valued at $10,521,000 after acquiring an additional 1,400 shares in the last quarter. Metis Global Partners LLC increased its stake in Stryker by 10.2% during the fourth quarter. Metis Global Partners LLC now owns 16,841 shares of the medical technology company's stock worth $6,064,000 after purchasing an additional 1,561 shares during the period. Finally, US Bancorp DE lifted its position in shares of Stryker by 0.5% during the fourth quarter. US Bancorp DE now owns 182,825 shares of the medical technology company's stock worth $65,829,000 after purchasing an additional 976 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the sale, the director now owns 14,895 shares of the company's stock, valued at $5,705,827.65. The trade was a 14.16 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the transaction, the director now owns 3,642,075 shares of the company's stock, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.20% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Needham & Company LLC restated a "buy" rating and set a $442.00 price target on shares of Stryker in a report on Friday, March 21st. Truist Financial lifted their price objective on shares of Stryker from $409.00 to $413.00 and gave the stock a "hold" rating in a research report on Thursday, January 30th. Canaccord Genuity Group upped their price objective on Stryker from $420.00 to $435.00 and gave the stock a "buy" rating in a research report on Wednesday, January 29th. Citigroup reaffirmed a "buy" rating and issued a $450.00 price target on shares of Stryker in a report on Wednesday, February 26th. Finally, Wells Fargo & Company lifted their price target on shares of Stryker from $427.00 to $435.00 and gave the stock an "overweight" rating in a research note on Wednesday, January 29th. Five equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $423.53.

Stryker Trading Up 1.1 %

NYSE SYK traded up $3.83 during mid-day trading on Thursday, reaching $360.94. 1,349,722 shares of the stock were exchanged, compared to its average volume of 1,356,479. The business's fifty day simple moving average is $368.69 and its 200 day simple moving average is $372.95. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The stock has a market capitalization of $137.77 billion, a PE ratio of 46.51, a PEG ratio of 2.93 and a beta of 0.93. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last released its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period in the prior year, the business earned $3.46 earnings per share. On average, research analysts anticipate that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.93%. Stryker's payout ratio is currently 43.30%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.